Core Insights - The FDA has officially confirmed that β-nicotinamide mononucleotide (NMN) can be legally sold as a dietary supplement, marking a significant regulatory shift in the U.S. market [1][2] - This regulatory relaxation highlights a deeper industrial competition between China and the U.S., as Chinese companies, which control 90% of global NMN raw material production, face challenges in exporting raw materials while struggling to sell finished products domestically due to stricter regulations [1][5] - Scientific controversies surrounding NMN's efficacy and safety cast a shadow over its commercial potential, with limited clinical trials and high costs limiting its market appeal primarily to high-net-worth individuals [1][9] Regulatory Landscape - The FDA's change in stance is attributed to a revision of the "drug preemption" clause, allowing NMN to be classified as a dietary supplement without requiring proof of health benefits, only safety assessments [2][4] - In contrast, China's regulatory framework remains cautious, with no formal approval for NMN as a food additive or health supplement, reflecting a more stringent approach to food safety standards [4][5] Market Dynamics - Chinese companies like Ginkgo BioWorks and Aibin Chemical are leveraging their technological capabilities in the production of NMN, but they primarily export raw materials or sell through cross-border e-commerce platforms due to domestic regulatory hurdles [5][7] - Despite having a strong position in raw material supply, Chinese firms lag in brand recognition and market presence compared to international giants, with limited sales of NMN products in domestic markets [5][7] Scientific and Commercial Challenges - The scientific basis for NMN's anti-aging claims is rooted in NAD+ metabolism, but the transition from animal studies to human applications remains uncertain, with only 19 registered clinical trials globally [7][9] - The high cost of NMN supplementation, which can reach thousands of yuan annually, raises questions about its value proposition compared to lifestyle interventions that can also enhance NAD+ levels at a lower cost [9]

Group 1 - The company, Yabao Chemical, announced on September 30 that it has signed strategic cooperation agreements with leading firms such as Heng Rui Pharmaceutical and Su Yan, aiming to establish long-term, stable, and trustworthy relationships with core partners [1] - This collaboration is expected to enhance the company's ability to expand cooperation dimensions and deepen the level of collaboration, reflecting the high recognition of the company's comprehensive strength by industry-leading enterprises [1]

Core Viewpoint - The resignation of Mr. Kang Litiao, the Deputy General Manager of Yabian Chemical, is effective immediately upon the delivery of his written resignation to the company's board of directors [1] Company Summary - Mr. Kang's original term was set from February 25, 2025, to February 24, 2028 [1] - As of the announcement date, Mr. Kang did not hold any shares in the company [1] - There are no unfulfilled commitments that Mr. Kang is obligated to fulfill [1]

Core Viewpoint - The resignation of senior management personnel, Kang Litiao, from Yabao Chemical Co., Ltd. due to personal reasons, effective immediately upon the board's receipt of the resignation letter [1] Group 1 - Kang Litiao resigned from the position of Deputy General Manager and will not hold any position in the company after his resignation [1] - His original term was set from 2025 to 2028 [1] - As of the announcement date, he did not hold any shares in the company and had no unfulfilled commitments [1]

雅本化学股份有限公司（以下简称"公司"）董事会于近日收到公司高级管 理人员康立涛先生递交的书面辞职报告。康立涛先生因个人原因辞去公司副总经 理职务，辞职后不在公司担任任何职务。康立涛先生的辞职自书面辞职报告送达 公司董事会之日起生效。 康立涛先生的副总经理职务原定任期为 2025 年 2 月 25 日至第六届董事会任 期届满之日，即 2025 年 2 月 25 日至 2028 年 2 月 24 日止。截至本公告披露日， 康立涛先生未持有公司股份，不存在应当履行而未履行的承诺事项。康立涛先生 辞去公司副总经理职务后，将继续严格遵守《上市公司董事和高级管理人员所持 本公司股份及其变动管理规则（2025 年修订）》《深圳证券交易所上市公司自 律监管指引第 18 号——股东及董事、高级管理人员减持股份（2025 年修订）》 等相关规定。 康立涛先生任职期间勤勉尽责，在深化主业发展和探索多元发展方面贡献突 出。公司及董事会对康立涛先生在公司任职期间为公司的发展所作出的贡献表示 衷心的感谢。 特此公告。 雅本化学股份有限公司 证券代码：300261 证券简称：雅本化学 公告编号：2025-073 雅本化学股份有限公司 关 ...

2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司上海雅本化学有限公司（以下简称 "上海雅本"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相担保 的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临 时股东大会审议通过了上述议案。 二、担保的进展情况 证券代码：300261 证券简称：雅本化学 公告编号：2025-072 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 1、上海雅本 公司名称：上海雅本化学有限公司 为满足日常经营发展需要，上海雅本向宁波银行股份有限公司苏州分行 （以下简称"宁波银行苏州分行"）申请了不超过人民币 8,000 万元的授信额 ...

证券日报网讯 9月17日晚间，雅本化学发布公告称，截至本公告日，公司累计对外担保金额（即目前公 司已签署并生效的担保协议总金额）为人民币168，200万元，占公司最近一期经审计净资产的 83.81%；累计提供对外担保余额（由公司提供担保取得的贷款余额）为人民币61，935.74万元，占公司 最近一期经审计净资产的30.86%。上述担保均是公司为合并报表范围内子公司提供的担保，不存在逾 期担保和涉及诉讼担保的情形。公司及下属子公司不存在违规担保和其他对合并报表外单位担保的情 况。 （文章来源：证券日报） ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-071 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司上海雅本化学有限公司（以下简称 "上海雅本"）、南通雅本化学有限公司（以下简称"南通雅本"）办理银行 授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上 披露的《关于公司为子公司提供担保及子公司互相担保的公告》（公告编号： 2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股东大会审议通过了 上述议案。 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》，公司同意为南通雅本申请银行项目贷款提供担保，担 保方式为连带责任保证担保，额度不超过人民币 2,500 万元，借款期限不超过 36 个月，主要用于支付项 ...

Group 1 - The company Yabao Chemical (300261) stated on September 15 that its NMN products have not applied for EFSA certification [1]

Group 1 - The core viewpoint of the article highlights that Amino Chemicals Limited (ACL), a subsidiary of Yabao Chemical, has maintained stable operations over the years [1] - For the first half of 2025, ACL achieved operating revenue of 30.4416 million yuan [1]